X0303 4 2008-11-11 0 0001088856 CORCEPT THERAPEUTICS INC CORT 0001024003 COOK JOSEPH C JR C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 1 0 0 0 Common Stock 484600 I By Joint Account Common Stock 995238 I By Farview Mgmt Co. Common Stock 2008-11-11 4 A 0 17471 1.45 A 193993 I By GRAT Stock option (right to buy) 7.00 2012-04-17 Common Stock 50000 50000 D Stock Option (right to buy) 7.00 2013-11-23 Common Stock 25000 25000 D Stock option (right to buy) 2.70 2017-12-19 Common Stock 15000 15000 D Warrants 2.77 2008-03-25 2015-03-24 Common Stock 88261 88261 I By GRAT Stock Option (right to buy) 2.23 2018-06-10 Common Sotck 15000 15000 D These securities are held by Farview Management Co., LLP, of which the reporting person is a general partner. Acquired from the issuer pursuant to the Amendment to Registration Rights Agreement dated November 11, 2008 in full satisfaction of cash liquidated damages owed under the Registration Rights Agreement dated as of March 14, 2008. The shares of common stock were valued at $1.45 per share, the closing market price of the common stock on the NASDAQ Capital Market on November 11, 2008. Immediately exercisable subject to a right of repurchase by Corcept Therapeutics Incorporated that shall lapse at the rate of 20% of the total option shares on 4/17/2003 and an additional 1.67% of the total option shares on each monthly anniverary of 4/17/2003 thereafter. Immediately exercisable subject to a right of repurchase by Corcept Therapeutics Incorporated that shall lapse at the rate of 20% of the total option shares on 11/23/2004 and an additional 1.67% of the total option shares on each monthly anniverary of 11/23/2004 thereafter. Exercisable with respect to 8.3334% of the total option shares on each monthly anniversary of June 11, 2007 so that the entirety of the option grant will vest within one year. Exercisable with respect to 8.3334% of the total option shares on each monthly anniversary of June 10, 2008 so that the entirety of the option grant will vest within one year. /s/ Joseph K. Belanoff, CEO of Corcept Therapeutics Incorporated attorney-in-fact 2008-11-13